EODData

MEMBERSHIP REGISTER LOG IN

FRA, 4LN2: CAPRICOR THERAP. DL-001

20 Jan 2026
LAST:

20.50

CHANGE:
 0.40		OPEN:
20.00		HIGH:
20.50		ASK:
0.00		VOLUME:
330
CHG(%):
1.99		PREV:
20.10		LOW:
20.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
20 Jan 2620.0020.5020.0020.50330
19 Jan 2620.1020.1020.1020.10500
16 Jan 2620.2020.2020.1520.15220
15 Jan 2620.7520.7520.7020.70220
14 Jan 2620.7020.7020.7020.70220
13 Jan 2620.4520.4520.3020.30220
12 Jan 2620.0020.0520.0020.05220
09 Jan 2621.3521.3521.0021.00220
08 Jan 2621.9021.9021.4021.40220
07 Jan 2621.8021.8021.1521.15220

PROFILE

Name:CAPRICOR THERAP. DL-001
About:Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:10865 Road to the Cure, San Diego, CA, United States, 92121
Website:https://www.capricor.com
ISIN:US14070B3096
LEI:5493002ZI5PDLXV4DX14

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-20.52 
Forward P/E:-24.84 
PEG Ratio:-0.49 
Price to Sales:115.99 
Price to Book:15.18 
Operating Margin:-7.79 
Return on Assets:-0.49 
Return on Equity:-1.08 
Revenue:9.44M 
Shares:45.72M 
Market Cap:937.2M 

TECHNICAL INDICATORS

MA5:20.430.3%
MA10:20.610.5%
MA20:21.645.5%
MA50:14.8038.5%
MA100:10.25100.0%
MA200:9.35119.3%
STO9:24.32
STO14:9.28 
RSI14:30.43 
WPR14:-90.72 
MTM14:-4.40
ROC14:-0.18 
ATR:0.79 
Week High:20.751.2%
Week Low:20.002.5%
Month High:25.8526.1%
Month Low:20.00119.3%
Year High:26.0527.1%
Year Low:3.73449.6%
Volatility:498.51 

RECENT SPLITS

Date Ratio
05 Jun 20191-10